Clearmind Medicine (CMND, Financial) has officially started its U.S. clinical trial operations at the Yale School of Medicine’s Department of Psychiatry. This marks the full activation of all intended sites necessary for their Phase I/IIa clinical trial targeting Alcohol Use Disorder (AUD), enabling the commencement of patient enrollment.
The company has successfully completed all preparatory steps required for the trial. This includes securing the Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), and obtaining Institutional Review Board (IRB) approvals at each participating site. Additionally, Clearmind has deployed its Electronic Data Capture (EDC) system to streamline the trial process and has successfully imported its drug candidate, CMND-100, into the United States post-manufacture.
